Yoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, Junji Tsurutani, Takeshi Yoshida, Kiyohiro Sakai, Miki Nakura, Ryo Sakamoto, Chihiro Makimura, Yoichi Ohtake, et al. Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain. Oncology letters. 2023. 26. 2. 355-355
Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo. Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma. Case Reports in Medicine. 2023. 2023. 1-4
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, et al. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands). 2023. 177. 44-50
Kensuke Suzuki, Hiroshi Harada, Masayuki Takeda, Chisato Ohe, Yoshiko Uemura, Akihiko Kawahara, Shunsuke Sawada, Akira Kanda, Bhaswati Sengupta, Hiroshi Iwai. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report. BMC Medical Genomics. 2022. 15. 1. 6-6
Method using a ret fusion gene as a biomarker to select non-small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
Lectures and oral presentations (20):
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancer
(Cancer Res (2021) 81 (13_Supplement): CT011. 2021)
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
(AACR 2019 2019)
T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC
(World Conference on Lung Cancer 2017 2017)
A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)
(World Conference on Lung Cancer 2017 2017)
Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
(World Conference on Lung Cancer 2017 2017)
日本サポーティブケア学会
, IASLC
, JAPAN SOCIETY OF CLINICAL ONCOLOGY
, THE JAPANESE CANCER ASSOCIATION
, 日本臨床腫瘍学会
, THE JAPAN LUNG CANCER SOCIETY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE